Protocol

Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis - an open Randomized, Controlled, Clinical Trial

The CaVenT Study Group

Working Protocol - Amendment 04 – August 2007
CONTENTS

Investigators 5
CaVenT study group 7
1 Synopsis 9
2 Background 11
3 Objectives 17
4 Hypothesis 17
5 Patient population 18
6 Methods 19
7 Definitions 24
8 Statistics 27
9 Ethical considerations 28
10 Milestones 28
11 Trial organization 29
12 Publication 30

References 31

Appendix 1 (Patient Information/Approval formular) 35
Appendix 2 (VEINES-QoL and EQ-D5 formulars) 39
Investigators:

Principal Investigator:  Professor Per Morten Sandset, MD, PhD  
Department of Hematology, Ullevål University Hospital (UUS)  
NO-0407 Oslo, Norway  
Tel.: +47 22119247  Fax.: +47 22119040  
E-mail: p.m.sandset@medisin.uio.no

Co-investigator:  Professor Nils-Einar Kløw, MD, PhD,  
Department of Cardiovascular Radiology, UUS  
Tel.: +47 22119415  Fax.: +47 22119415  
E-mail: n.e.klow@medisin.uio.no

Research Fellow:  Tone Enden, MD  
Departments of Hematology and Radiology, UUS  
Tel.: +47 23016097  Mobile: 91716584  Fax.: +47 22119040  
E-mail: tone.enden@medisin.uio.no

Statistician:  Professor Leiv Sandvik, PhD, Statistician  
Research Forum, UUS  
Tel.: +47 23015057  Fax.: +47 22118479  
E-mail: leiv.sandvik@uus.no

Angiologist:  Consultant Carl-Erik Slagsvold, MD, PhD,  
Department of Vascular Diagnosis and Research, Oslo Vascular Center  
Aker University Hospital (AUS)  
Tel.: +47 22894000  
E-mail: carlerikslagsvold@yahoo.no

Hematologists:  Consultant Pål Andre Holme, MD, PhD  
Department of Hematology, Rikshospitalet-Radiumhospitalet (RR) HF  
Tel.: +47 23070000  
E-mail: Holme@rikshospitalet.no

Consultant Waleed Ghanima, MD  
Department of Internal Medicine, Central Hospital in Østfold  
Tel.: +47 69860000  
E-mail: Waleed.Ghanima@so-hf.no

Consultant Anne Mette Njaastad, MD  
Department of Hematology, AUS  
Tel.: +47 22894865  
E-mail: AnneMette.Njaastad@akersykehus.no

Radiologists:  Consultant Geir Hafsahl, MD  
The Interventional Centre, RR  
Tel.: +47 23070000  
E-mail: geir.hafsahl@rikshospitalet.no

Consultant Lars Olaf Holmen, MD  
Department of Radiology, Østfold Hospital Trust Fredrikstad  
Tel.: +47 69860000  
E-mail: Lars.Olaf.Holmen@so-hf.no
Consultant Gunnar Sandbæk, MD, PhD
Department of Radiology, Aker University Hospital
Tel.: +47 22 89 40 00
E-mail: gunnar.sandbaek@medisin.uio.no

Research Nurse: Torill Moan
Department of Hematology, UUS
Tel.: +47 22119242
E-mail: torillnyborg.moan@uus.no

Technician: Marie-Christine Mowinckel
Department of Hematology/ Hematological Res Lab, UUS
Tel.: +47 23015783
E-mail: Marie-Christine.Mowinckel@uus.no
## The CavenT Study Group

### Interventional Centres

<table>
<thead>
<tr>
<th>Participating Centre</th>
<th>Collaborator</th>
<th>E-mail</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aker University Hospital (AUS)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematologist</td>
<td>Anne Mette Njåstad, MD</td>
<td><a href="mailto:AnneMette.Njaastad@akersykehus.no">AnneMette.Njaastad@akersykehus.no</a></td>
</tr>
<tr>
<td>Radiologist</td>
<td>Gunnar Sandbæk, MD, PhD</td>
<td><a href="mailto:gunnar.sandbaek@medisin.uio.no">gunnar.sandbaek@medisin.uio.no</a></td>
</tr>
<tr>
<td><strong>Østold Hospital Trust Fredrikstad</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematologist</td>
<td>Waleed Ghanima, MD</td>
<td><a href="mailto:Waleed.Ghanima@so-hf.no">Waleed.Ghanima@so-hf.no</a></td>
</tr>
<tr>
<td>Radiologist</td>
<td>Lars Olav Holmen, MD</td>
<td><a href="mailto:Lars.Olaf.Holmen@so-hf.no">Lars.Olaf.Holmen@so-hf.no</a></td>
</tr>
<tr>
<td><strong>Rikshospitalet-Radiumhospitalet (RR)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematologist</td>
<td>Pål Andre Holmen, MD, PhD</td>
<td><a href="mailto:Holme@rikshospitalet.no">Holme@rikshospitalet.no</a></td>
</tr>
<tr>
<td>Radiologist</td>
<td>Geir Hafsahl, MD</td>
<td><a href="mailto:geir.hafsahl@rikshospitalet.no">geir.hafsahl@rikshospitalet.no</a></td>
</tr>
<tr>
<td><strong>Ullevaal University Hospital (UUS)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematologist</td>
<td>Per Morten Sandset, MD, PhD</td>
<td><a href="mailto:p.m.sandset@medisin.uio.no">p.m.sandset@medisin.uio.no</a></td>
</tr>
<tr>
<td>Radiologist</td>
<td>Nils-Einar Kløw, MD, PhD</td>
<td><a href="mailto:n.e.klow@medisin.uio.no">n.e.klow@medisin.uio.no</a></td>
</tr>
</tbody>
</table>
## The CavenT Study Group

### Participating Centres

#### Helse Sør RHF:

<table>
<thead>
<tr>
<th>Participating Centre</th>
<th>Collaborator</th>
<th>E-mail</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blefjell sykehus HF</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Rjukan</td>
<td>Oddvar Øygarden, MD</td>
<td><a href="mailto:Oddvar.Oygarden@blefjellsykehus.no">Oddvar.Oygarden@blefjellsykehus.no</a></td>
</tr>
<tr>
<td>• Notodden</td>
<td>Thomas Baisa, MD</td>
<td><a href="mailto:tbaisa@online.no">tbaisa@online.no</a></td>
</tr>
<tr>
<td>• Kongsberg</td>
<td>Lydia Klevstul, MD</td>
<td><a href="mailto:lidia.klevstul@blefjellsykehus.no">lidia.klevstul@blefjellsykehus.no</a></td>
</tr>
<tr>
<td><strong>Ringerike sykehus HF</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vigdis Stenberg, MD</td>
<td><a href="mailto:vigdis.stenberg@Ringerike-sykehus.no">vigdis.stenberg@Ringerike-sykehus.no</a></td>
</tr>
<tr>
<td><strong>Sykehuset Buskerud HF</strong></td>
<td>Jacob Dalgaard, MD, PhD</td>
<td><a href="mailto:jakob.dalggaard@sb-hf.no">jakob.dalggaard@sb-hf.no</a></td>
</tr>
<tr>
<td><strong>Sykehuset i Vestfold HF</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Tønsberg</td>
<td>Per Arne Standal, MD</td>
<td><a href="mailto:per.standal@siv.no">per.standal@siv.no</a></td>
</tr>
<tr>
<td>• Larvik</td>
<td>Sverre Nyhus, MD</td>
<td><a href="mailto:sverre.nyhus@siv.no">sverre.nyhus@siv.no</a></td>
</tr>
<tr>
<td><strong>Sykehuset Telemark HF</strong></td>
<td>Erwin Müller, MD</td>
<td><a href="mailto:erwin.muller@sthf.no">erwin.muller@sthf.no</a></td>
</tr>
<tr>
<td><strong>Sørlandet sykehus HF</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Kristiansand</td>
<td>Jürgen Rolke, MD</td>
<td><a href="mailto:jurgen.rolke@sshf.no">jurgen.rolke@sshf.no</a></td>
</tr>
<tr>
<td>• Arendal</td>
<td>Yngve Benestad, MD</td>
<td><a href="mailto:yngve.benestad@sshf.no">yngve.benestad@sshf.no</a></td>
</tr>
<tr>
<td>• Flekkefjord</td>
<td>Morten Rønningen, MD</td>
<td><a href="mailto:mortenro@gmail.com">mortenro@gmail.com</a></td>
</tr>
</tbody>
</table>

#### Helse Øst RHF:

<table>
<thead>
<tr>
<th>Participating Centre</th>
<th>Collaborator</th>
<th>E-mail</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sykehuset Asker og Bærum HF</strong></td>
<td>Arnljot Tveit, MD</td>
<td><a href="mailto:arnljot.tveit@broadpark.no">arnljot.tveit@broadpark.no</a></td>
</tr>
<tr>
<td><strong>Akershus Universitetssykehus HF</strong></td>
<td>Willy Aasebø, MD</td>
<td><a href="mailto:willy.aasebo@ahu.no">willy.aasebo@ahu.no</a></td>
</tr>
<tr>
<td><strong>Lovisenberg Diakonale sykehus</strong></td>
<td>Hege Pihlstrøm, MD</td>
<td><a href="mailto:hege.pihlstrom@lds.no">hege.pihlstrom@lds.no</a></td>
</tr>
<tr>
<td><strong>Diakonhjemmets sykehus</strong></td>
<td>Torbjørn Holm, MD, PhD</td>
<td><a href="mailto:torbjorn.holm@diakonsyk.no">torbjorn.holm@diakonsyk.no</a></td>
</tr>
<tr>
<td><strong>Sykehuset Innlandet HF</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Gjøvik</td>
<td>Per Vandvik, MD, PhD</td>
<td><a href="mailto:per.vandvik@start.no">per.vandvik@start.no</a></td>
</tr>
<tr>
<td>• Lillehammer</td>
<td>Eystein Brandt, MD</td>
<td><a href="mailto:eystein.brandt@sykehuset-innlandet.no">eystein.brandt@sykehuset-innlandet.no</a></td>
</tr>
<tr>
<td>• Hamar</td>
<td>Øvind Bukten, MD</td>
<td><a href="mailto:buktenovvin@hotmail.no">buktenovvin@hotmail.no</a></td>
</tr>
<tr>
<td>• Elverum</td>
<td>Marianne Kalbakken, MD</td>
<td><a href="mailto:marianne.kalbakken@sykehuset-innlandet.no">marianne.kalbakken@sykehuset-innlandet.no</a></td>
</tr>
</tbody>
</table>
1 SYNOPSIS

Deep vein thrombosis (DVT) is a severe disease which may cause severe disability and which is sometimes fatal. Conventional treatment with low molecular weight heparin (LMWH) and oral anticoagulants is associated with some degree of long-term sequelae, i.e., post-thrombotic syndrome (PTS), in more than 60-80% of the patients. Systemic thrombolytic therapy reduces the risk of PTS, but is associated with an unacceptably high risk of bleeding complications, many being disabling or fatal. Catheter-directed thrombolytic (CDT) therapy is a novel treatment modality which has been introduced in many hospitals worldwide. Low dose fibrinolytic agents are delivered continuously and directly into the thrombus through a catheter until thrombus has dissolved. Although many, mostly small series, have suggested a beneficial effect of this costly treatment in terms of increased patency of the veins and improved short term functional outcome, there are no randomized clinical trials documenting its short and long-term efficacy and safety.

The present study is a randomized, open-label, multi-center clinical trial among hospitals in the Eastern and Southern Norway Health Authorities (Helse Øst and Sør). Patients with acute iliofemoral vein thrombosis will be randomized to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. A number of secondary outcomes include bleeding complications, recurrent thrombosis, quality of life (QoL), markers of importance for successful lysis and recurrent thrombosis, and whether PTS is related to patency at the end of treatment.

Our main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected iliofemoral vein segments after 6 months from <50% on conventional therapy to >80% after CDT. Our main long-term hypothesis is that CDT will improve long-term functional outcome, i.e., risk of PTS, assessed after 2 years, from >25% on conventional treatment to <10% after CDT. The estimated sample size is at least 100 evaluable patients in each group using a statistical significance (α) = 5% and a statistical power (1-β) = 80%.
2 BACKGROUND

Deep vein thrombosis (DVT) of the lower extremities is a common disease, which is associated with significant morbidity. The incidence of DVT is estimated as 1 event per 1,000 per year, which ranks it as one of the more common cardiovascular disorders. Furthermore, DVT is associated with several important short- and long-term outcomes. Short-term there are symptoms of pain and swelling due to inflammation and obstruction. In a small minority of cases, the condition leads to phlegmasia cerulea dolens in which extensive venous obstruction leads to ischemia or infarction of the extremity. Lastly, DVT can also lead to pulmonary embolism (PE), which can be fatal. Long-term sequelae of DVT include recurrent venous thromboembolism (VTE), post-thrombotic syndrome (PTS), and chronic thromboembolic pulmonary hypertension.

Anticoagulation therapy is the basic treatment of DVT, which purpose is to inhibit the thrombotic process and the inflammatory response so that the thrombus can be cleared by endogenous fibrinolysis. Anticoagulation therapy thereby alleviates acute symptoms, prevents PE, and recurrent events. In most cases, anticoagulation is achieved acutely with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) therapy, followed by long term anticoagulation with oral vitamin K antagonists (eg warfarin).

Anticoagulation therapy is highly efficacious for the prevention of recurrent VTE, PE, and death, but the ability to prevent PTS as an outcome is less clear. PTS is thought to be a result of residual venous stenosis and damage to the venous valves which together cause venous hypertension. Venous hypertension leads to chronic edema and fibrin deposition in the interstitial tissues, which in turn bring about poor oxygen exchange. Insufficient oxygenation induces skin changes, pain and, in severe cases, chronic ulceration.

Several studies have addressed the epidemiology of PTS, i.e., the incidence of PTS over time, its risk factors, the relationship between vein patency and development of PTS, and the usefulness of compression stockings to prevent PTS following a first episode of acute DVT treated with anticoagulation alone. The incidence of moderate or severe PTS varied across these studies, but in general increased over time. Moderate to severe PTS developed in 2% to 11% of patients with DVT provided that compression stockings were worn at some early point after the acute DVT. Elastic compression stockings may reduce the risk of PTS by approximately 50%. Risk factors for severe PTS identified by some, but not all of these studies, were recurrent ipsilateral DVT, extent of initial thrombus, and obesity. Although the role of return of vein patency has not been established, it may still be an appropriate surrogate for long-term outcomes.
Thrombolytic agents, such as streptokinase (SK), urokinase (UK), and recombinant tissue plasminogen activator (rt-PA) are, theoretically, ideal adjuvants to standard anticoagulation therapy because they potentially dissolve thrombi, promote early vein recanalization, and thereby, minimize vein stenosis and valve dysfunction\textsuperscript{13,14}. Therefore, treatment strategies incorporating these agents with anticoagulation may be more effective than those using anticoagulation alone for the prevention of PTS. In addition, in the minority of cases with phlegmasia cerulea dolens, thrombolytic therapies may prove limb saving. However, despite the theoretical advantages and a history of more than 30 years of use, thrombolytic therapy has not been widely embraced for DVT treatment due to poor results.

Table 1  Summary results for the trials comparing streptokinase (SK) to intravenous unfractionated heparin (UFH); Values in parentheses are percent of cases.

<table>
<thead>
<tr>
<th>Study</th>
<th>SK Events/N (%)</th>
<th>UFH Events/N (%)</th>
<th>Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efficacy = significant lysis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robertson 1\textsuperscript{15}</td>
<td>5/8 (63)</td>
<td>1/8 (13)</td>
<td>9.4 (0.9, 98.1)</td>
</tr>
<tr>
<td>Kakkar\textsuperscript{16}</td>
<td>7/10 (70)</td>
<td>2/20 (20)</td>
<td>8.2 (1.1, 58.7)</td>
</tr>
<tr>
<td>Robertson 2\textsuperscript{17}</td>
<td>5/9 (56)</td>
<td>1/7 (14)</td>
<td>6.2 (0.6, 62.1)</td>
</tr>
<tr>
<td>Tsapogas\textsuperscript{18}</td>
<td>10/19 (53)</td>
<td>1/15 (7)</td>
<td>12.6 (1.7, 96.5)</td>
</tr>
<tr>
<td>Porter\textsuperscript{19}</td>
<td>13/24 (54)</td>
<td>8/26 (31)</td>
<td>2.6 (0.8, 8.2)</td>
</tr>
<tr>
<td>Elliot\textsuperscript{20}</td>
<td>17/26 (65)</td>
<td>0/25 (0)</td>
<td>188.4 (3.4, 10494)</td>
</tr>
<tr>
<td>Arnesen\textsuperscript{21}</td>
<td>15/21 (71)</td>
<td>5/21 (24)</td>
<td>7.6 (1.9, 29.3)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>72/117 (62)</strong></td>
<td><strong>18/112 (16)</strong></td>
<td><strong>8.5 (4.4, 16.3)</strong></td>
</tr>
<tr>
<td><strong>Major Hemorrhage</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robertson</td>
<td>2/8 (25)</td>
<td>0/8 (0)</td>
<td>11.9 (0.2, 843)</td>
</tr>
<tr>
<td>Kakkar</td>
<td>3/30 (39)</td>
<td>2/10 (20)</td>
<td>1.6 (0.2, 11.8)</td>
</tr>
<tr>
<td>Tsapogas</td>
<td>4/19 (21)</td>
<td>0/15 (0)</td>
<td>17.0 (0.3, 1022)</td>
</tr>
<tr>
<td>Porter</td>
<td>4/24 (17)</td>
<td>1/26 (4)</td>
<td>4.2 (0.5, 34)</td>
</tr>
<tr>
<td>Elliot</td>
<td>2/26 (8)</td>
<td>0/25 (0)</td>
<td>9.4 (0.1, 607)</td>
</tr>
<tr>
<td>Schulman\textsuperscript{22}</td>
<td>3/17 (18)</td>
<td>1/19 (5)</td>
<td>3.3 (0.4, 29.4)</td>
</tr>
<tr>
<td>Arnesen</td>
<td>2/21 (10)</td>
<td>2/21 (10)</td>
<td>1.0 (0.1, 7.1)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>20/115 (16)</strong></td>
<td><strong>6/124 (5)</strong></td>
<td><strong>3.9 (1.5, 10.3)</strong></td>
</tr>
</tbody>
</table>
Table 2  Summary results for the trials comparing urokinase (UK) to intravenous unfractionated heparin (UFH); Values in parentheses are percent of cases.

<table>
<thead>
<tr>
<th>Study</th>
<th>UK Events/N (%)</th>
<th>UFH Events/N (%)</th>
<th>Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Efficacy = significant lysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldhaber</td>
<td>1/8 (13)</td>
<td>1/9 (11)</td>
<td>1.1 (0.1, 2.9)</td>
</tr>
<tr>
<td>Kiil</td>
<td>1/11 (9)</td>
<td>1/9 (11)</td>
<td>0.8 (0, 14.9)</td>
</tr>
<tr>
<td>Total</td>
<td>2/19 (11)</td>
<td>2/18 (11)</td>
<td>1.0 (0.1, 7.2)</td>
</tr>
<tr>
<td></td>
<td>Major Hemorrhage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldhaber</td>
<td>0/8 (0)</td>
<td>1/9 (11)</td>
<td>0.2 (0, 16.3)</td>
</tr>
<tr>
<td>Kiil</td>
<td>0/11 (0)</td>
<td>3/9 (33)</td>
<td>0.8 (0, 2.8)</td>
</tr>
<tr>
<td>Total</td>
<td>0/19 (0)</td>
<td>4/18 (22)</td>
<td></td>
</tr>
</tbody>
</table>

Table 3  Summary results for the trials comparing recombinant tissue plasminogen activator (rt-PA) to intravenous unfractionated heparin (UFH); Values in parentheses are percent of cases.

<table>
<thead>
<tr>
<th>Study</th>
<th>rt-PA Events/N (%)</th>
<th>UFH Events/N (%)</th>
<th>Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Efficacy = significant lysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldhaber</td>
<td>15/53 (28)</td>
<td>0/12 (0)</td>
<td>10.1 (0.8, 999)</td>
</tr>
<tr>
<td>Turpie 2</td>
<td>6/29 (21)</td>
<td>2/30 (7)</td>
<td>3.7 (0.6, 29)</td>
</tr>
<tr>
<td>Turpie 1</td>
<td>7/12 (58)</td>
<td>0/12 (0)</td>
<td>34.1 (2.0, 999)</td>
</tr>
<tr>
<td>Total</td>
<td>28/94 (30)</td>
<td>2/54 (4)</td>
<td>11.7 (2.6, 53)</td>
</tr>
<tr>
<td></td>
<td>Major Hemorrhage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldhaber</td>
<td>1/53 (2)</td>
<td>0/12 (0)</td>
<td>0.7 (0.01, 999)</td>
</tr>
<tr>
<td>Turpie 2</td>
<td>0/29 (0)</td>
<td>0/30 (0)</td>
<td>0.3 (0, 22000)</td>
</tr>
<tr>
<td>Turpie 1</td>
<td>1/12 (0)</td>
<td>0/12 (0)</td>
<td>1.0 (0.02, 43)</td>
</tr>
<tr>
<td>Verahaeghe</td>
<td>0/11 (0)</td>
<td>3/9 (33)</td>
<td>7.3 (0, 2.8)</td>
</tr>
<tr>
<td>Total</td>
<td>0/105 (2)</td>
<td>3/63 (48)</td>
<td>0.4</td>
</tr>
</tbody>
</table>

documentation of its efficacy and high short-term risk of bleeding\textsuperscript{27}. Overall only a few hundred patients have been evaluated in randomized clinical trials. The effects of SK treatment versus heparin are summarized in Table I, the effects of urokinase versus heparin in Table II, and that of rt-PA versus heparin in Table III. The overall clinical effects are shown in Table IV.
**Table 4** Summary results of all trials of thrombolytic therapy for acute DVT (after\textsuperscript{13}).

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Success rate (% with significant lysis)</th>
<th>Major hemorrhage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unfractionated heparin</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>SK</td>
<td>62</td>
<td>16</td>
</tr>
<tr>
<td>SK high dose</td>
<td>Uninterpretable</td>
<td>Uninterpretable</td>
</tr>
<tr>
<td>SK low dose</td>
<td>27</td>
<td>15</td>
</tr>
<tr>
<td>UK</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>rt-PA</td>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td>rt-PA high dose</td>
<td>6</td>
<td>29</td>
</tr>
<tr>
<td>rt-PA local administration</td>
<td>27</td>
<td>10</td>
</tr>
<tr>
<td>Catheter directed (UK and rt-PA)</td>
<td>83</td>
<td>11</td>
</tr>
</tbody>
</table>

Several published studies using ultrasound imaging have demonstrated considerable endogenous ability to lyse thrombi after conventional anticoagulation therapy\textsuperscript{2}. One year after acute DVT, somewhere between 30% and 73% of patients will normalize their ultrasound findings. Earlier in the disease course, patency rates are lower, demonstrating that over time there is continued recanalization of the vein. The studies do not describe PTS incidence and whether or not development of the condition correlates with recanalization status. Without this information, it is difficult to answer the important question of whether or not early recanalization protects against development of PTS.

*Catheter-directed thrombolytic therapy (CDT)* is a relatively new technique for treatment of DVT\textsuperscript{13,28} and its efficacy has recently been reviewed\textsuperscript{29}. It involves application of the thrombolytic agent directly into the thrombus using a catheter with multiple side holes. The catheter is passed into the clot under radiographic guidance. The venous puncture may be central or peripheral to the thrombosed vein. For thrombolysis of the pelvic and the femoral veins, the access was in the early studies of the internal jugular, or the contralateral or ipsilateral femoral veins. Subsequent investigators have used the ipsilateral popliteal vein with success and this appears to be the site of choice. The thrombolytic agent is administered over 1-4 days until dissolution of the clot is apparent. Both UK, alteplase (Actilyse®), reteplase (Rapilysin®) and tenecteplase (Metalyse®) has been used, but UK is no longer available in the market, and only alteplase may be given as a continuous iv infusion, preferably at 0.001-0.02 mg/kg/hour\textsuperscript{30,31}. Heparin therapy should be given concomitantly intravenously probably at subtherapeutic doses\textsuperscript{29,30,32,33}, corresponding to a 1.2-1.7 times prolongation of aPTT.
The decision to discontinue the drug is based on daily venographic examinations through the indwelling catheter. Depending on the findings the catheter may be pulled out, the infusion continued, or the catheter repositioned. To obtain flow in the veins balloon inflation may be performed at the follow-up. Thrombolytic agents are given until there is no more evidence of thrombosis or until there is little improvement in venographic appearance. After 72-96 hours thrombolysis is discontinued. Adjuvant therapies include angioplasty, angioplasty with stents, thrombectomy, and surgically created arterio-venous fistulas.

So far, there are no randomized clinical trials with long-term follow-up on the efficacy of CDT therapy, but at least 15 case series have been reported\textsuperscript{29,34-37}. Combining the studies, 263 patients received this type of therapy for thrombosis of the iliofemoral veins or inferior vena cava. 221 (84\%) patients were considered to have successful short-term outcomes based on venographic appearance and 13 (4.9\%) patients had bleeding severe enough to warrant transfusion. Long term outcomes were not reported, and the authors did not describe the proportion of patients requiring adjuvant therapy.

A National DVT Registry was established in North-America to analyze results in a large number of patients treated with CDT\textsuperscript{38}. This registry included 473 patients with documented lower extremity DVT treated with CDT, but follow-up data included only 287 patients who received 312 treatments. Thrombi subjected to lysis included either ilio-femoral vein thrombosis in 71\% of cases and femoro-popliteal vein thrombosis in 25\% of cases. The mean age of patients was 47.5 years and the mean duration of infusion was 53 h. All patients had six months of therapy with oral anticoagulants following CDT and many had heparin as well. Complete lysis was obtained in 31\% of patients, 50-99\% lysis in 52\% and <50\% lysis in 17\%. Successful lysis was not related to location of the thrombus. The overall primary patency rate was 80\% at 12 months, with better patency for ilio-femoral segments than the femoro-popliteal segments. Major bleeding complications occurred in 11\% of patients; 39\% of these at the venous insertion site, 13\% were retroperitoneal hematoma. Minor bleeding events occurred in 16\% of patients, again most often at the venous entry site. There was one fatal intracranial hemorrhage, one subdural hematoma, and 6 pulmonary emboli of which one was fatal. Thus, the overall mortality rate from lysis was 0.4\%. There was no data on PTS.

If the PTS differs between standard therapy and thrombolytic therapy then the quality of life may differ between patients also. Comerota assessed health-related quality of life in patients after CDT therapy compared to a group of patients treated with standard anticoagulation therapy\textsuperscript{39}. The delayed functional outcome and wellbeing scores were significantly better in the thrombolytic therapy group. Although this study had some methodological shortcomings\textsuperscript{13}, the findings are still suggestive that thrombolytic therapy may offer improved quality of life in patients who achieve successful thrombolysis.
Compared to historical data of anticoagulation and intravenous thrombolysis, CDT probably has higher recanalization rates. The studies so far, including one RCT with 6 months follow-up and 35 patients\textsuperscript{40}, have been promising, but unfortunately no high-quality randomized studies with long-term follow-up have been performed. Experimental data indicate that valves of the femoral veins may be preserved\textsuperscript{41,42}. It is therefore possible that PTS may be reduced. However, long term studies have not been performed. In the absence of well-designed randomized clinical studies both for early findings, the implications of early patency for long-term clinical results, the complications, and the costs related to treatment, CDT therapy for DVT should at present be considered experimental treatment. Still, some Norwegian hospitals including Aker and Ullevål University Hospitals, Rikshospitalet, and the Østfold Hospital Trust Fredrikstad, do provide this high-intensive treatment to selected patients. A case-series with careful follow-up at Aker University Hospital has recently been published\textsuperscript{31}.

In the present study, we aim to investigate the role of CDT therapy for treatment of acute DVT as compared with established treatment with low molecular weight heparin. The study will be an open-label, randomized study of patients with first-time acute DVT of the affected limb, and our major outcome parameter will be the frequency of PTS as related to early venographic patency. The results of this study have the potential to properly define the role of this costly treatment in the future.
3 OBJECTIVES

3.1 PRIMARY OBJECTIVES
To investigate whether catheter-directed thrombolytic therapy for first-time acute DVT of the iliofemoral veins may:
3.1.1 increase patency rate at 6 months.
3.1.2 reduce the risk of PTS at 2 years.

3.2 SECONDARY OBJECTIVES
3.2.1 To investigate frequency of clinically relevant bleeding related to the procedure.
3.2.2 To investigate effects on quality of life (QoL).
3.2.3 To investigate cost-effectiveness of treatment.
3.2.4 To investigate the procedural success of CDT.
3.2.5 To identify markers of importance for successful thrombolysis.
3.2.6 To investigate patency at 2 years.
3.2.7 To investigate PTS at 6 and 60 months.
3.2.8 To investigate whether presence or absence of PTS at any time point is related to patency at end of treatment.
3.2.9 To investigate prevalence of vein anomalies (and need for angioplasty or stents).
3.2.10 To investigate prevalence of underlying thrombophilia.
3.2.11 To investigate frequency of recurrent VTE during follow-up.
3.2.12 To identify markers of importance for recurrent thrombosis.

4 HYPOTHESES
Our main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected iliofemoral vein segments after 6 months from <50% on conventional therapy to >80% after CDT. Our main long-term hypothesis is that CDT will improve long-term functional outcome, i.e., risk of PTS, assessed after 2 years, from >25% on conventional treatment to <10% after CDT.
5 PATIENT POPULATION

5.1 INCLUSION CRITERIA
5.1.1 Age 18-75 years.
5.1.2 Onset of symptoms <21 days.
5.1.3 Objectively verified DVT (ultrasonography, venography, computed tomography, or magnetic resonance imaging) localized in the upper half of the thigh, the common iliac vein or the combined iliofemoral segment.
5.1.4 Informed consent (Appendix 1).

5.2 EXCLUSION CRITERIA
5.2.1 Anticoagulant therapy prior to trial entry for >7 days.
5.2.2 Contraindications to thrombolytic therapy, including bleeding diathesis.
5.2.3 Indications for thrombolytic therapy, e.g., phlegmacia coerolia dolens or isolated vena cava thrombosis.
5.2.4 Severe anemia (hemoglobin <8 g/dL).
5.2.5 Thrombocytopenia (platelets <80·10^9/L).
5.2.6 Severe renal failure – creatinine clearance <30 ml/min. Creatinine clearance will be calculated according to the following formula:

\[
\text{Creatinine clearance (ml/min)} = \frac{b \times (140 - \text{age (yrs)}) \times \text{body weight (kg)}}{\text{serum creatinine (µmol/L)}}
\]

\[b=1.23 \text{(females)}; 1.04 \text{(males)}\]
5.2.7 Severe hypertension, i.e. persistent systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg.
5.2.8 Pregnancy and thrombosis ≤7 days post-partum (may be included after 7 days post-partum).
5.2.9 Less than 14 days post-surgery or post-trauma (may be included after 14 days).
5.2.10 History of subarachnoidal or intracerebral bleeding.
5.2.11 Disease with life expectancy <24 months.
5.2.12 Drug abuse or mental disease that may interfere with treatment and follow-up.
5.2.13 Former ipsilateral proximal DVT.
5.2.14 Malignant disease requiring chemotherapy.
5.2.15 Any thrombolytic therapy within 7 days prior to trial inclusion.
6 METHODS

6.1 DESIGN
Multi-center, open-label, randomized clinical study on the effect and safety of CDT therapy as compared with conventional therapy for the treatment of acute, first-time ilio-femoral DVT. The study will be a collaborative study of hospitals belonging to the Eastern and Southern Norway Health Authorities (Helse Øst and Sør).

6.2 PATIENT RECRUITMENT
Eligible patients (section 5) will be invited to participate in the study. Informed consent (Appendix 1) in accordance with the revised Helsinki Declaration must be obtained from the patient before randomization.

6.3 RANDOMIZATION
Patients will be randomized by sealed numbered envelopes using block randomization. Each envelope will contain information on treatment allocation. A new patient will be allocated the lowest numbered envelope. Treatment will be open-label, but stratified for extension of DVT, i.e., only femoral or iliofemoral DVT.

6.4 TREATMENT
6.4.1 Acute treatment
Patients will be randomized to one of the following treatment groups:

<table>
<thead>
<tr>
<th>Group</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Catheter-directed thrombolytic therapy with rt-PA in addition to conventional treatment with low molecular weight heparin (for details – see 6.4.2)</td>
</tr>
<tr>
<td>II</td>
<td>Conventional treatment with low molecular weight heparin (see 6.4.3)</td>
</tr>
</tbody>
</table>

Drugs will be ordered from the hospital’s pharmacy according to local routines.
- Group I will be given rt-PA (Actilyse®) combined with unfractionated heparin and followed by low molecular weight heparin (LMWH) and warfarin.
- Group II, the conventional treatment arm, will be given LMWH, either sc dalteparin (Fragmin®), 200 IU/kg od, or enoxaparin (Klexane®), 1.5 mg/kg od, according to local routines, and warfarin.
6.4.2 Group I - Catheter-Directed Thrombolytic (CDT) therapy – procedures

- **Anticoagulant and fibrinolytic therapy**
  - Discontinue oral anticoagulants - INR should be <1.5 before the procedure.
  - In case of prior sc LMWH therapy treatment should be discontinued at least 8 h before the procedure, and in case of prior UFH treatment APTT (Cephotest®) should be adjusted to 40-60 sec during the procedure (see below).
  - An iv bolus dose of UFH, 5000 U, should be given followed by continuous iv UFH\(^1\) infusion at 15 U/kg/h. Adjust dose to keep APTT (Cephotest®) at 40-60 sec, first adjustment 6-12 h after start of treatment.
  - During the thrombolytic treatment keep APTT (Cephotest®) at 40-60 sec.
  - At the completion of thrombolytic treatment:
    - **✓** discontinue UFH
    - **✓** give sc LMWH after 1 h, (either dalteparin, Fragmin®, 200 U/kg bid, or enoxaparin, Klexane®, 1.5 mg/kg bid).
    - **✓** Oral warfarin (Marevan®) will be initiated according to local routines.
    - **✓** LMWH will be discontinued when INR has been in therapeutic range (2.0-3.0) for at least 24 hours, but should not be given for less than total 4-5 days.

- **Interventional procedures.** In an interventional radiology unit, an introducer will be inserted into an appropriate vein, preferentially the popliteal vein, guided by ultrasound to prevent puncture of the artery or laceration of the vein wall and to secure only a single puncture. If possible, the wire and catheter should be introduced above the proximal part of the thrombus (use fitting-sized perfusion catheters, e.g., 10, 20, 30, or 50 cm). A venography should then be performed to disclose the topography of the thrombus. CDT may be discontinued if introduction of the catheter through the occluded segment is not successful. Catheters should be properly fixed to the skin.

  The perfusion catheter (and the perfusion wire) should cover the central to peripheral part of the thrombus. Rt-PA (Actilyse®), 20 mg diluted in 500 ml 0.9% NaCl, will be infused at 0.01 mg/kg/h. Maximal dose infused will be 20 mg/24 h. The rt-PA dosage may be split into two catheters using lower consentration, keeping flow the same.

---

\(^1\) A suitable working solution should be made to contain UFH 40 U/ml in 0.9% NaCl, e.g., mix 20 000 U of UFH in 500 ml 0.9% NaCl or 40 000 U in 1000 ml 0.9% NaCl. The infusion rate (ml/h) then reflects total units of UFH per 24 hrs in thousands, e.g., 25 ml/h corresponds to 25 000 U/24 h, 30 ml/h 30 000 U/24 h, and so on.
After insertion of catheter, venography, and start of iv UFH and iv rt-PA infusion, treatment will continue in medical wards. Blood pressure and pulse and the puncture site are assessed 4 times a day. Hemostasis is also monitored by daily analysis of hemoglobin, fibrinogen, D-dimer, INR, and platelet counts. APTT is monitored twice daily for adjustment of heparin dose. The patient will be encouraged to use the muscle pump of the leg while in bed. No food and drink restrictions.

Effect of treatment will be assessed by venography at least every 24 hrs, and catheters repositioned accordingly. Treatment should normally not continue for >96 h. At the end of treatment, the catheters will be removed immediately and hemostasis obtained by manual compression of the puncture site. Pressure will be continued for 2 hrs with a roll while the patient is immobilized.

- **Stents.** Balloon dilatation and placement of venous stents will be performed at the discretion of the operator to establish flow and to obtain <50% residual stenosis.

- **Concomitant medication during procedure.** During the interventional procedure concomitant use of other antithrombotic agents should be avoided because of increased risk of bleeding. This includes antiplatelet agents (e.g., acetylsalicylic acid, thienopyridines, GPIIb/IIIa inhibitors, non steroidal anti-inflammatory agents, or other) or anticoagulants (e.g., low molecular weight heparin, pentasaccharide, warfarin, or other). Concomitant use of ACE-inhibitors appears to increase the risk of anafylactoid reactions.

**6.4.3 Group II – conventional treatment with LMWH**
Patients allocated the conventional treatment arm will be given sc LMWH, either dalteparin (Fragmin®), 200 U/kg od, or enoxaparin (Klexane®), 1.5 mg/kg od, according to local hospital routines, and simultaneous warfarin (Marevan®) according to local routines. LMWH will be discontinued when INR has been in therapeutic range (2.0-3.0) for at least 24 hours, but should not be given for less than total 4-5 days.

**6.4.4 Subacute and chronic phase after DVT**
Patients will be treated with warfarin for at least 6 months with target INR 2.0-3.0. All patients will be advised to use knee-high compression stockings, grade II, for 6 months.
6.5 VISITS AND PROCEDURES DURING FOLLOW-UP
End-point assessment will be performed by a vascular surgeon with no previous contact or knowledge of patients' medical history or treatment allocation. At each visit the patients will explicitly be told not to reveal treatment allocation.

6.5.1 Visit 1 (trial entry – at hospital admission/)
6.5.1.1 Case history and general clinical examination.
6.5.1.2 Compression ultrasonography or venography, alternatively CT or MRI angiography diagnosing acute iliofemoral DVT.
6.5.1.3 Laboratory screening (hemoglobin, platelets, leukocytes, creatinine, ASAT, ALAT, GT, bilirubin, INR, APTT, D-Dimer, cholesterol, and CRP).
6.5.1.4 Thrombophilia screening (collection of blood samples).
6.5.1.5 Assessment of baseline QoL before treatment using VEINES-QoL and EQ-D5 (Appendix 2).
6.5.1.6 Assessment of baseline clinical score using Villalta543 score and the C classification of CEAP, see Definitions.

6.5.2 Visit 2 (hospital stay)
6.5.2.1 Daily assessment of hemoglobin, platelets, fibrinogen, APTT, INR, and D-Dimer, and bilateral leg circumference.
6.5.2.2 Daily venography will be performed in patients allocated CDT.
6.5.2.4 Bleeding complications.

6.5.3 Visit 3 – 6 m ± 2 weeks
6.5.3.1 Clinical history – recurrent thrombosis – malignancy.
6.5.3.2 Clinical PTS scores according to Villalta and CEAP. Bilateral leg circumference.
6.5.3.3 Assessment of functional venous obstruction by air-plethysmography.
6.5.3.4 Ultrasonographic assessment of postthrombotic changes, patency, and reflux 44-47.
6.5.3.5 Quality of Life (QoL) assessment (Appendix 2).
6.5.3.6 D-dimer testing, INR, thrombophilia screening (if previously inconclusive).

6.5.4 VISIT 4 – 12 m ± 4 weeks
Telephone interview – recurrent thrombosis – malignancy.
6.5.5 VISIT 5 – 24 m ± 4 weeks
6.5.5.1 Clinical history – recurrent thrombosis – malignancy.
6.5.5.2 Clinical PTS scores according to Villalta and CEAP. Bilateral leg circumference.
6.5.5.3 Assessment of functional venous obstruction by air-plethysmography.
6.5.5.4 Ultrasonographic assessment of postthrombotic changes, patency, and reflux.
6.5.5.5 Quality of Life (QoL) assessment (Appendix 2).
6.5.5.6 D-dimer, INR, thrombophilia screening (if previously inconclusive).

6.5.6 VISIT 6 – 36 m ± 4 weeks
Telephone interview – recurrent thrombosis – malignancy.

6.5.7 VISIT 7 – 48 m ± 4 weeks
Telephone interview – PTS screening – recurrent thrombosis – malignancy.

6.5.8 VISIT 8 – 60 m ± 8 weeks
6.5.8.1 Clinical history – recurrent thrombosis – malignancy.
6.5.8.2 Clinical PTS scores according to Villalta and CEAP. Bilateral leg circumference.
6.5.8.3 Ultrasonographic assessment of postthrombotic changes, patency, and reflux.
6.5.8.4 Assessment of functional venous obstruction by air-plethysmography.
6.5.8.5 Quality of Life (QoL) assessment (Appendix 2).
7 DEFINITIONS

7.1 Post-Thrombotic Syndrome (PTS)

7.1.1 The Villalta Score\textsuperscript{5,43}

PTS will be evaluated using the Villalta score, which scores PTS based on five symptoms and six objective signs (each item graded from 0 to 3):

Five symptoms: heaviness, pain (spontaneous or during deambulation), cramps, pruritus, and paresthesia.

Six signs: pretibial edema, induration of the skin, hyperpigmentation, new venous ectasia, redness, pain during calf compression.

A total score of 5-14 indicates mild to moderate PTS, whereas a score of 15 or more indicates severe PTS. A lower limb venous ulcer indicates severe PTS regardless of the sum of the remaining signs and symptoms. The Villalta Score is quantitative and useful for longitudinal assessment of PTS.

7.1.2 The Clinical-Etiology-Anatomic-Pathophysiologic (CEAP) classification\textsuperscript{48,49}

This is a classification of Clinical (dermatological) signs, Etiology, Anatomic distribution and Pathophysiologic dysfunction:

<table>
<thead>
<tr>
<th>Clinical signs</th>
<th>Class 0</th>
<th>No visible or palpable signs of venous disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class 1</td>
<td>Teleangiectases or reticular veins</td>
<td></td>
</tr>
<tr>
<td>Class 2</td>
<td>Varicose veins</td>
<td></td>
</tr>
<tr>
<td>Class 3</td>
<td>Edema</td>
<td></td>
</tr>
<tr>
<td>Class 4</td>
<td>a. pigmentation, eczema</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. lipodermatosclerosis, atrophia blanche</td>
<td></td>
</tr>
<tr>
<td>Class 5</td>
<td>Healed ulceration (and skin changes as defined above)</td>
<td></td>
</tr>
<tr>
<td>Class 6</td>
<td>Active ulceration (and skin changes as defined above)</td>
<td></td>
</tr>
<tr>
<td>Etiological classification</td>
<td>Congenital, primary, secondary</td>
<td></td>
</tr>
<tr>
<td>Anatomic distribution</td>
<td>Superficial, deep, or perforator, alone or in combination</td>
<td></td>
</tr>
<tr>
<td>Pathophysiological dysfunction</td>
<td>Reflux or obstruction, alone or in combination</td>
<td></td>
</tr>
</tbody>
</table>
7.2 Non-invasive assessment of veins

7.2.1 Deep vein thrombosis

7.2.1.1 Acute deep vein thrombosis
The principal criterion is inability to completely compress the vein lumen when examining the vein in the transverse plane. Other possible findings are distention of the vein, absence of flow, loss of phasic flow, and visualization of clot.

7.2.1.2 Chronic thrombosis and postthrombotic changes
Absence of complete incompressibility indicates residual thrombosis. Other postthrombotic features are wall-thickening and intraluminal hyperechoic structure.

7.2.2 Flow
Using Doppler-ultrasound, flow will be graded as spontaneous flow, forced flow (on peripheral compression), and no flow (obstruction). Flow will also be examined in supine position.

7.2.3 Reflux
Using Doppler-ultrasound and a distal inflation cuff with the patient in standing position, reflux is defined as reversal of the velocity curve after distal pneumatic decompression lasting longer than 0.5 second.

7.2.4 Assessment of functional venous obstruction
Venous obstruction will be assessed by using air plethysmography. The patients will lie supine with the calf elevated (by a cushion) to the level of the heart. An occlusion cuff will be placed proximally on the thigh, and a recording cuff with a pressure of 6 mmHg will be placed on the calf. The proximal cuff will be inflated to 50 mmHg for 1 min. A venous outflow curve will be recorded when this cuff is deflated, and maximum outflow can then be calculated (delta mm/sec). Low outflow rates indicate presence of functional venous obstruction. The procedure will be performed on both legs.

7.2.5 Assessment of venous patency
Assessment of venous patency will include compressibility, flow and functional venous obstruction.
7.3 Evaluation of thrombolysis
Based on venography before and after CDT, thrombolysis will be graded by a scoring system\(^3^8\). Score=0 indicates an open vein, score=1 a partly occluded vein, and score=2 a completely occluded vein.

Each of the following 7 venous segments will be given a grade (0-2): IVC, the common iliac vein, the external iliac vein, the common femoral vein, the proximal and distal superficial femoral veins, and the popliteal vein. A total thrombus score before and after lysis will be calculated by adding the 7 scores. The difference between the pre- and postlysis thrombus scores divided by the prelysis score gives the grade of thrombolysis. Grade I=<50%; grade II=50-90%, and grade III=complete thrombolysis.

7.4 Bleeding Complications
7.4.1 Major bleeding – any bleeding associated with a reduction in hemoglobin by ≥2 g/100 mL or bleeding requiring transfusion of ≥2 U pack red blood cells or whole blood or bleeding in a critical organ, intracranial, retroperitoneal or pericardial or bleeding contributing to death.

7.4.2 Clinically relevant non-major bleeding – overt bleeding not meeting criteria for major bleeding but satisfying a priori criteria defined by the safety monitoring committee including for example skin hematomas >100 cm\(^2\), epistaxis lasting >5 min, being repetitive (≥2/24 h) or requiring intervention (packing, electrocoagulation), macroscopic hematuria – either spontaneous or lasting >24 h after instrumentation (catheter or surgery) of the urogenital tract, or any other bleeding type that is considered to have clinical consequences for the patient.

7.4.3 Trivial bleeding - all other overt bleeding episodes not meeting the criteria for clinically relevant bleeding.

7.5 Thrombophilia screening
Includes screening for antithrombin, protein C- and protein S deficiencies, factor V Leiden mutation, the prothrombin gene 20210GA allele variation and the methylene tetrahydrofolate reductase (MTHFR) mutation, homocystein, lupus anticoagulants and anticardiolipin antibodies.
8 STATISTICS

8.1 Sample size
Numerous studies indicate that conventional treatment, i.e., UFH or LMWH followed by oral anticoagulants is associated with PTS in more than 60-80% of the cases, whereas systemic thrombolytic therapy is associated with PTS in approximately 30% of the patients. More recent studies employing systematic use of elastic compression stockings suggest PTS in approximately 25% of the patients. In the present study, we will assume that the rate of PTS after 2 years will be at least 25% in those allocated conventional therapy as compared with less than 10% in those given CDT. For patency after 6 months we assume that the rate is less than 50% in those allocated conventional treatment as compared with at least 80% in those given CDT. With a significance level of $\alpha \leq 5\%$ and a statistical power (1-$\beta$) of $\geq 80\%$, we will need to randomize approximately 100 patients in each group.

Also as presented in our hypotheses, we assume that venous patency after 6 months occurs in less than 50% in those allocated conventional treatment as compared to at least 80% in those given adjunctive CDT. It may then be shown that with a significance level of 5% and a statistical power $\geq 80\%$, 76 patients must be included to test this short-term hypothesis. We plan to analyse patency rates after 6 months based on the first 100 patients with 6 months patency data. This analysis will be repeated when 200 patients have 6 months patency data.

8.2 Statistical methods
All statistical analysis will be performed according to the intention-to-treat principle. If ineligible patients are mistakenly included, they may be excluded (ref Ferguson et al BMJ 2002), apart from this, no other post-randomization exclusions will be made. The effect of treatment will be determined using 2x2 tables with assessment of the difference between patent vessels and prevalence of PTS, relative risks, and odds ratios with 95% confidence limits. The prevalence of clinically relevant bleeding, PTS, vein anomalies, thrombophilia, recurrent DVT will be determined using point estimates with 95% confidence intervals. A stratification analysis will be carried out using the Mantel-Haenzel method. Differences in baseline characteristics may be adjusted for using a multivariate logistic model. This may be done if there are substantial differences between the two groups, and if the variable(s) is probably or certainly associated with the outcome measure, e.g., age and previous VTE. Missing data on end-point variables will be scored as previous score or last/worst score carried forward.
9 ETHICAL CONSIDERATIONS

This study will recruit patients with proximal DVT. Even though the efficacy and safety of CDT for the treatment of acute proximal DVT remains to be established, some hospitals in many countries now offer CDT to selected patients with severe DVT, especially when the DVT extends into the caval vein. In the present study, non-trial CDT to selected patients with severe DVT will be left to the discretion of the responsible physician.

The study will be performed in accordance with the revised Helsinki Declaration and Good Clinical Practice (GCP). The study will only start after approval with the Regional Ethical Committee and the Norwegian Medical Agency. All patients will be given study specific identification codes and all data will be stored in a secured database on a secured server for research at the Ullevål University Hospital. This server as well as data management will be controlled by the Patient Protection Ombud at the Ullevål University Hospital. A non-linked database will provide information on the patients’ contact information to allow follow-up. A biobank will be established at Ullevål University Hospital after approval.

10 MILESTONES

Q1-2006  First patient randomized
Q4-2007  Last patient randomized
Q2-2008  Six months follow-up of all patients for primary efficacy parameter patency
Q2-3-2008 Reporting of study design and primary efficacy parameter patency
Q4-2009  Two-years follow-up of all patients for primary efficacy parameter PTS
Q4-Q1-09-10 Reporting of primary efficacy parameter PTS
Q4-2012  Five years follow-up of last patient for patency and PTS.
11 TRIAL ORGANIZATION

11.1 GENERAL ORGANIZATION

The study is an investigator initiated study which will be run independently of the pharmaceutical industry. The study is financially supported by a grant from Eastern Norway Health Authority (doctoral fellow; Helse Øst grant no 2005-090).

The study will be a major collaborative effort among hospitals of the Eastern and Southern Norway Health Authorities (Helse Øst and Sør). All hospitals will be invited to participate in the study. Patients allocated to conventional treatment will be treated at the local hospital, whereas patients allocated CDT will be treated at Ullevål and Aker University Hospitals, the National Hospital and the Central Hospital in Østfold.

11.2 COMMITTEES

11.2.1 Executive committee

- Per Morten Sandset (chair) – UUS – Hematologist
- Nils-Einar Kløw – UUS – Radiologist
- Leiv Sandvik – UUS – Statistician
- Tone Enden – UUS – Research fellow – Resident in Radiology
- Carl-Erik Slagsvold – AUS – Angiologist
- Anne Mette Njåstad – AUS – Hematologist
- Gunnar Sandbaek – AUS – Radiologist
- Pål Andre Holme – RR – Hematologist
- Geir Hafsahl – RR – Radiologist
- Waleed Ghanima – Østfold Hospital Trust Fredrikstad – Hematologist
- Lars Olav Holmen – Østfold Hospital Trust Fredrikstad – Radiologist

11.2.2 Steering committee

- Executive committee (chair Per Morten Sandset)
- One member from each collaborating hospital

11.2.3 Safety and monitoring committee

- Professor emeritus Ulrich Abildgaard
- Professor Frank Brosstad, Rikshospitalet-Radiumhospitalet, Oslo
12 PUBLICATION

Results of this study will be published in international medical journals, but will also be communicated to the general population whenever appropriate. The results may potentially have great interest for the scientific community, for health-providers in decision making, and for the general population. Publication will follow the Vancouver convention. Tone Enden will be the first author of these publications.
REFERENCES


40. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A


Appendix 1

FORESPØRSEL OM Å DELTA I EN FORSKNINGSSTUDIE:

CaVenT-studien – kateterbasert trombolyse ved akutt dyp venetrombose

Denne forespørselen om å delta i forskningsprosjektet ”CaVenT” går til pasienter som legges inn med akutt blodpropp i lår- og bekkenvener ved sykehus i Helseregion Sør og Øst.

Du bestemmer selv


Bakgrunn

Undersøkselser viser at du har fått en blodpropp i en samleblodåre (vene) i låret og/eller i bekkenet. Tilstanden kalles dyp venetrombose. Standardbehandlingen ved akutt dyp venetrombose er blodfortynnende medisin, først sprøyter med lavmolekylært heparin (inneholder legemidlene Fragmin eller Klexane) i 4-8 dager og deretter tabletter (legemidlet Marevan) i minst 3-6 måneder. Målet med behandlingen er å stoppe utviklingen av blodproppen, forhindre at blodproppen løsner og går til lungene og å redusere plagesomme senfølger i form av smerter, hevelse og hudforandringer. Slike senfølger kalles posttrombotisk syndrom. Om lag en fjerdedel av pasientene utvikler posttrombotisk syndrom i løpet av de første 2 årene etter standardbehandling for blodropp.

De siste årene er det utviklet en ny behandling for å løse opp blodpropp som kalles kateterbasert trombolyse. Behandlingen er beskrevet i detalj under. Foreløpige resultater tyder på at denne behandlingen kan løse opp blodproppen raskere og forebygge senplagene, men så langt har det ikke vært gjennomført studier som kan gi gode svar på dette.

Prosjektets formål

Hensikten med dette forskningsprosjektet er å avklare om tilleggsbehandling med kateterbasert trombolyse gir bedre resultat i akutt fase og færre plager på lang sikt uten økt risiko for bivirkninger sammenliknet med standard blodfortynnende medisin alene.

Om kateterbasert trombolyse/blodpropplosende behandling


Dersom det i forløpet av behandlingen påvises en unormal blodåre (vene), oftest en medfødt innsnevring, som kan forklare hvorfor blodpropp oppsto, vil vi vurdere å gi tilleggsbehandling ved å
utvide blodåren ved hjelp av et ballongkateter, eventuelt legge inn en stent (forsterkning). Dette vil sikre normal blodstrøm etter behandlingen.

Behandling med blodpropp-oppløsning utføres ved flere av de store sykehusene i regionen, og dersom ditt sykehus ikke kan utføre behandlingen, vil du bli overført til et av disse.

Etter avsluttet kateterbasert behandling vil du få vanlig behandling med lavmolekylært heparin og Marevan og bli fulgt opp etter gjeldende retningslinjer ved ditt lokalsykehus.

**Gjennomføring**

For å kunne gjøre en vitenskapelig sammenlikning av resultatene, vil det bli foretatt en trekning slik at halvparten av pasientene vil få standard behandling, mens den andre halvparten vil få kateterbasert trombolyse i tillegg. Du gis skriftlig og muntlig informasjon om forskningsprosjektet når du legges inn.

Deltagelse i studien medfører i tillegg til vanlig behandling og oppfølging, ekstra samtaler med lege (noen som telefonkonsultasjon) og enkelte undersøkelser (ultralyd, blodprøver) ved ulike tidspunkt i de påfølgende 2 år. Uansett behandling vil vi kontakte deg regelmessig, enten per telefon (etter 12, 36 og 48 måneder) eller ved kontrollundersøkelse (etter 6, 24 og 60 måneder). Undersøkelsene omfatter ultralydunderøkelse og blodprøver.

**Risiko ved behandlingen**

Kateterbasert trombolyse medfører en litt økt risiko for blødning sammenliknet med den vanlige behandlingen. Det vanligste er mindre blødning ved innstikksstedet der plastrøret er lagt inn. Hos noen få pasienter har det vært rapportert blødninger andre steder, mest alvorlig er blødninger i tarm og hode. Dersom slik blødning oppstår, vil vi stoppe den trombolytiske behandlingen og sette i gang tiltak for å behandle blødningen etter gjeldende rutiner ved sykehusene.

**Blodprøver og biobank**


**Slik ivaretas dine prøver og personopplysninger**

Hvem som har vurdert prosjektet

Regional komité for medisinsk forskningsetikk, Øst-Norge, har vurdert prosjektet, og har ingen innvendinger mot at det gjennomføres. Forskningsbiobanken er meldt til Sosial- og helsedirektoratet, som ikke har innsigelser til opprettelse av biobanken.

Økonomi

Forskningsprosjektet er et samarbeid mellom sykehusavdelinger i Helse Sør og Øst. Prosjektet er delvis finansiert gjennom forskningsmidler fra Helse Øst. Det er ikke aktuelt å samarbeide med industri, og det er heller ikke aktuelt med kommersialisering av produkter. Prosjektansvarlig og andre som arbeider med prosjektet har ingen form for økonomisk vinning knyttet til prosjektet.

Dine rettigheter


Prosjektansvarlig – mer informasjon

Dersom du har flere spørsmål om studien eller biobanken kan du kontakte en av de prosjektansvarlige legene (se under) eller legen som er ansvarlig for oppfølging ved ditt sykehus (se under).

---

Per Morten Sandset
Avd. overlege, professor, dr. med
Prosjektansvarlig
Hematologisk avdeling, UUS

Per Morten Sandset
Avd. overlege, professor, dr. med
Prosjektansvarlig
Hematologisk avdeling, UUS

---

Tone Enden
Lege, stipendiat
Prosjektleder, UUS
Tlf UUS 22 11 80 80, calling nr. 581 78389
e-mail: tone.enden@uus.no

Prosjektansvarlig lege ved ditt sykehus er:

Navn:
Tittel:
Adresse:
Telefon:
CaVenT-studien

Samtykke – prosjektdeltaker

Deltakelse i studien er basert på ditt frivillige, informerte samtykke. Dersom du ønsker informasjon utover det som framkommer i dette informasjonsskrivet og den muntlige informasjonen du har mottatt/vil få, har du full anledning til å be om dette.

Dersom du etter å ha fått den informasjon du synes er nødvendig, sier ja til å delta i studien, må du signere samtykkeerklæringen.

Jeg, ____________________________________________ (navn med blokkbokstaver), bekrefter at jeg har mottatt skriftlig informasjon om studien, har fått anledning til å innhente den informasjon jeg har hatt behov for, og er villig til å delta i prosjektet.

Signatur ____________________________ Dato ____________________________
   (sign. prosjektdeltaker)                 (datert av prosjektdeltaker)

Informasjon om studien er gitt av:

Lege, ____________________________________________ (navn med blokkbokstaver)

Signatur ____________________________ Dato ____________________________
   (sign. lege)
**Appendix 2: VEINES-QoL and EQ-D5**

<table>
<thead>
<tr>
<th>Spørreskjema om helse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opplysningene vil være til hjelp for å holde rede på hvordan du har det, og om hvordan du klarer å utføre dine vanlige aktiviteter.</td>
</tr>
</tbody>
</table>

Vis hvilke utsagn som passer best på **din helsetilstand i dag** ved å sette et kryss i en av rutene utenfor hver av gruppene nedenfor.

### Gange
- Jeg har ingen problemer med å gå omkring. [ ]
- Jeg har litt problemer med å gå omkring. [ ]
- Jeg er sengeliggende. [ ]

### Personlig stell
- Jeg har ingen problemer med personlig stell. [ ]
- Jeg har litt problemer med å vaske meg eller kle meg. [ ]
- Jeg er ute av stand til å vaske meg eller kle meg. [ ]

### Vanlige gjøremål (*f.eks. arbeid, studier, husarbeid, familie- eller fritidsaktiviteter)*.
- Jeg har ingen problemer med å utføre mine vanlige gjøremål. [ ]
- Jeg har litt problemer med å utføre mine vanlige gjøremål. [ ]
- Jeg er ute av stand til å utføre mine vanlige gjøremål. [ ]

### Smerte/ubehag
- Jeg har verken smerte eller ubehag. [ ]
- Jeg har moderat smerte eller ubehag. [ ]
- Jeg har sterk smerte eller ubehag. [ ]

### Angst/depresjon
- Jeg er verken engstelig eller deprimert. [ ]
- Jeg er noe engstelig eller deprimert. [ ]
- Jeg er svært engstelig eller deprimert. [ ]
Besvar hvert spørsmål nedenfor ved å krysse av svaret som angitt. Hvis du er usikker på hva du skal svare, vennligst svar etter beste evne.

Disse spørsmålene er om din oppfatning av beina dine.

1. I løpet av de 4 siste ukene, hvor ofte har du hatt noen av disse plagene i beina?

   (Sett ett kryss på hver linje)

<table>
<thead>
<tr>
<th></th>
<th>Daglig</th>
<th>Flere ganger i uka</th>
<th>Omtrent én gang i uka</th>
<th>Sjeldnere enn én gang i uka</th>
<th>Aldri</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Tunge bein</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>2. Vondt i beina</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>3. Hevelse</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>4. Kramper om natta</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>5. Varme eller brennende følelse</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>6. Urolige bein</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>7. Banking</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>8. Kløe</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>9. Prikking</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
</tbody>
</table>

2. Når på dagen er plagene i beina mest uttalte? (Sett ett kryss)

   ☐ 1 Når jeg våkner ☐ 4 Om natta
   ☐ 2 Midt på dagen ☐ 5 Når som helst i løpet av dagen
   ☐ 3 På slutten av dagen ☐ 6 Aldri

3. Sammenlignet med for ett år siden, hvordan vil du vurdere dine plagene i beina nå? (Sett ett kryss)

   ☐ 1 Mye bedre nå enn for ett år siden ☐ 4 Noe verre nå enn for ett år siden
   ☐ 2 Noe bedre nå enn for et år siden ☐ 5 Mye verre nå enn for et år siden
   ☐ 3 Omtrent det samme nå som for et år siden ☐ 6 Jeg hadde ingen plagene i beina i fjor

4. Følgende spørsmål gjelder daglige aktiviteter. Setter plagene i beina begrensninger for dine daglige aktiviteter? Hvis « ja », i hvilken grad?
### 5. I løpet av de 4 siste ukene, har du hatt noen av disse problemene i jobb eller i daglige aktiviteter på grunn av plagene i beina?

<table>
<thead>
<tr>
<th>(Sett ett kryss på hver linje)</th>
<th>Jeg jobber ikke</th>
<th>JA, begrenser meg mye</th>
<th>JA, begrenser meg litt</th>
<th>NEI, begrenser meg ikke</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Daglige aktiviteter på jobb.</td>
<td>□ 0</td>
<td>□ 1</td>
<td>□ 2</td>
<td>□ 3</td>
</tr>
<tr>
<td>b. Daglige aktiviteter hjemme (husarbeid, småjobber, hagearbeid, o.l.)</td>
<td>□ 1</td>
<td>□ 2</td>
<td>□ 3</td>
<td></td>
</tr>
<tr>
<td>c. Fritidsaktiviteter hvor du må stå lenge (selskap, ta buss, handle o.l.)</td>
<td>□ 1</td>
<td>□ 2</td>
<td>□ 3</td>
<td></td>
</tr>
<tr>
<td>d. Fritidsaktiviteter hvor du må sitte lenge (kino, teater, på reise o.l.)</td>
<td>□ 1</td>
<td>□ 2</td>
<td>□ 3</td>
<td></td>
</tr>
</tbody>
</table>

### 6. I løpet av de 4 siste ukene, i hvilken grad har plagene i beina kommet i veien for samvær med familie, venner, naboer eller grupper? (Sett ett kryss)

- □ 1 Ikke i det hele tatt
- □ 2 Lett
- □ 3 Moderat
- □ 4 Ganske stor
- □ 5 Svær

### 7. Hvor mye smerter har du hatt i beina i løpet av de 4 siste ukene? (sett ett kryss)

- □ 1 Ingen
- □ 2 Svært lite
- □ 3 Lite
- □ 4 Moderat
- □ 5 Mye
- □ 6 Svært mye

### 8. Disse spørsmålene er om hvordan du føler deg, og om hvordan du har hatt det de siste 4 ukene som følge av plagene i beina. For hvert spørsmål, kryss av for det svaret som passer best med hvordan du har følt deg. Hvor mye i løpet av de 4 siste ukene-

<table>
<thead>
<tr>
<th>(Sett ett kryss på hver linje)</th>
<th>Hele tiden</th>
<th>Det meste av tiden</th>
<th>Ganske ofte</th>
<th>Av og til</th>
<th>Sjelde n</th>
<th>Aldri</th>
</tr>
</thead>
</table>

41
<table>
<thead>
<tr>
<th></th>
<th>Spørsmål</th>
<th>☐ 1</th>
<th>☐ 2</th>
<th>☐ 3</th>
<th>☐ 4</th>
<th>☐ 5</th>
<th>☐ 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>har du vært bekymret for hvordan beina dine ser ut?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.</td>
<td>har du følt deg irritabel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.</td>
<td>har du følt at du har vært til byrde for familie eller venner?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d.</td>
<td>har du vært bekymret for å skumpe bort ting?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e.</td>
<td>har dine beins utseende påvirket ditt klesvalg?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Vennligst oppgi dato for utfyllingen: _____/_____/_______ (dag/måned/år)